WEBULL
WebtradeDownload

GSK (LSE:GSK) Reaffirmed Guidance And Declared A 17p Dividend, Is It 16% Below Fair Value?

Simply Wall St · 2d ago

GSK (LSE:GSK) put income and visibility in focus with its latest update. The group declared a third interim dividend of 17p per share and reaffirmed 2026 turnover guidance at the upper half of its 3% to 5% range.

Recent price action has been mixed. The 7 day share price return declined 4.99% even as a 30 day share price gain of 2.70% and dividend news, FDA approvals for Jemperli and Hibsago, and oncology trial updates kept GSK firmly in focus.

Over a longer horizon, the picture looks steadier. Total shareholder return of 5.76% over 1 year and 44.30% over 3 years reflects momentum that has built over time, even if short term trading around £18.28 reflects shifting views on earnings resilience and pipeline risk.

Scan how GSK compares with other income and healthcare plays by reviewing a curated set of 4 dividend fortresses that pair yield with financial resilience.

Bulls point to GSK’s pipeline and income profile, while bears focus on softer earnings and recent share price weakness. Which side do the current valuation markers lean toward as investors weigh the next move?

Most Popular Narrative: 16% Undervalued

GSK last closed at £18.28, while the most followed narrative pegs fair value at £21.73 using a 7.56% discount rate. The gap between price and modelled worth is clear before even looking at the pipeline detail.

The main thing that has to go right is that GSK converts its enlarged late stage pipeline, particularly in oncology and long acting HIV and liver disease programs, into commercially meaningful products while delivering the planned £1.9b annual cost savings by 2029.

The Accelerate Growth program targeting £1.9b in annual cost savings by 2029, supported by site closures, manufacturing consolidation and productivity initiatives, is intended to self fund more than 20 Phase III starts while keeping operating margins stable to improving through the 2028 to 2030 loss of exclusivity period.

See why 224 investors see GSK as 16% undervalued.

Result: Fair Value of £21.73 (UNDERVALUED)

Still, the narrative frays quickly if the loss of exclusivity in key HIV drugs bites harder than expected, or if more late stage trials repeat the camlipixant setback.

Find out about the key risks to this GSK narrative.

Next Steps

The sentiment on GSK is mixed, with clear risks and clear rewards pulling in different directions. Move quickly from headlines to hard data and weigh the 3 key rewards and 3 important warning signs.

Looking for more investment ideas beyond GSK?

If GSK has sharpened your focus on income and resilience, broaden the search now. Fresh ideas often come from corners of the market you are not watching yet.